Evidence map›Paper›PMID 26840025›Full record

ArticleOncotarget2016

Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters.

Bryan Mitton, Katie Hsu, Ritika Dutta, Bruce C Tiu, Nick Cox, Kevin G McLure, Hee-Don Chae, Mark Smith, Elizabeth A Eklund, David E Solow-Cordero and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Targeting transcription factors in acute myeloid leukemia.International journal of hematology · 2019
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Bryan MittonDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Katie HsuDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Ritika DuttaDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Bruce C TiuDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Nick CoxMedicinal Chemistry Knowledge Center, Stanford ChEM-H, Stanford, CA, USA.
Kevin G McLureDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Hee-Don ChaeDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Mark SmithMedicinal Chemistry Knowledge Center, Stanford ChEM-H, Stanford, CA, USA.
Elizabeth A EklundDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
David E Solow-CorderoHigh-Throughput Bioscience Center, Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
Kathleen M SakamotoDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Stanford University · USStanford Medicine · USNorthwestern University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
The Role of CREB in Normal Myelopoiesis and LeukemogenesisR01HL075826 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAKAMOTO, KATHLEEN M · 2004 to 2013
$3.2M
Upgraded High-Content and High-Throughput siRNA Screening SystemS10RR026338 · NCRR · STANFORD UNIVERSITY · PI SOLOW-CORDERO, DAVID EDWARD · 2010 to 2010
$498k
INSTRUMENTATION FOR GENETIC AND CHEMICAL SCREENING: BIOCHEMISTRYS10RR019513 · NCRR · STANFORD UNIVERSITY · PI MEYER, TOBIAS · 2004 to 2004
$488k
NCI NIH HHS 2P30CA124435-04NCI NIH HHS P30 CA060553NCI NIH HHS P30 CA124435NCRR NIH HHS S10 RR019513NCRR NIH HHS S10RR019513NCRR NIH HHS S10 RR026338NCRR NIH HHS S10RR026338NHLBI NIH HHS R01 HL075826NHLBI NIH HHS R01 HL75826
6 · The paper itself

Abstract

The transcription factor CREB (cAMP Response Element Binding Protein) is an important determinant in the growth of Acute Myeloid Leukemia (AML) cells. CREB overexpression increases AML cell growth by driving the expression of key regulators of apoptosis and the cell cycle. Conversely, CREB knockdown inhibits proliferation and survival of AML cells but not normal hematopoietic cells. Thus, CREB represents a promising drug target for the treatment of AML, which carries a poor prognosis. In this study, we performed a high-throughput small molecule screen to identify compounds that disrupt CREB function in AML cells. We screened ~114,000 candidate compounds from Stanford University's small molecule library, and identified 5 molecules that inhibit CREB function at micromolar concentrations, but are non-toxic to normal hematopoietic cells. This study suggests that targeting CREB function using small molecules could provide alternative approaches to treat AML.

Indexed as

ApoptosisCell ProliferationCells, CulturedCyclic AMP Response Element-Binding ProteinHematopoietic Stem CellsHigh-Throughput Screening AssaysHumansLeukemia, Myeloid, AcuteLuciferasesPromoter Regions, GeneticReal-Time Polymerase Chain ReactionResponse ElementsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSmall Molecule LibrariesCREB1 protein, humanCyclic AMP Response Element-Binding ProteinLuciferasesRNA, MessengerSmall Molecule LibrariesCREBnovel therapeuticssmall molecule screen

Identifiers

PMID26840025
PMCPMC4890994
OpenAlexW2259477622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.